Sugi Predict

Sugi Predict / Compounds / SCHEMBL14212260

SCHEMBL14212260

SCHEMBL14212260

CC1(C)OB(c2ccc3c(c2)OCCO3)OC1(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 13/20 0.44
▸ LIPG Q9Y5X9 13/20 0.44
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA6 P23280 1/20 0.38
▸ CA5A P35218 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38
▸ CA5B Q9Y2D0 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ F11 P03951 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29634547 1.00 LPL (0.44) LPLLIPGCA1CA2CA9
SCHEMBL15335321 0.93 LPL (0.42) LPLLIPGCA1CA2CA9
SCHEMBL30544472 0.89 LPL (0.44) LPLLIPGCA1CA2CA9
SCHEMBL3148663 0.89 LPL (0.44) LPLLIPGCA1CA2CA9
SCHEMBL22816906 0.84 LPL (0.36) LPLLIPGCA1CA2CA9
SCHEMBL4427556 0.81 PRKCI (0.41) LPLLIPGF11
SCHEMBL1803570 0.81 LPL (0.41) LPLLIPGCA1CA2CA9
SCHEMBL29775936 0.81 PRKCI (0.41) LPLLIPGF11
SCHEMBL10074115 0.79 LPL (0.48) LPLLIPGCA1CA2CA9
SCHEMBL10074112 0.79 LPL (0.48) LPLLIPGCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 — — US disclosed
WO-2025134150-A1 BIPHENYL PYRIDINE RIGID COMPOUNDS WITH POLYCYCLIC HETEROCYCLES USEFUL AS DUAL IMMUNE CHECKPOINT INHIBITORS NATCO PHARMA LIMITED (IN) 2025-06-26 — — WO disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
US-20230365529-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
WO-2023130587-A1 WATER-SOLUBLE METHYLBENZENE ETHER DERIVATIVE, POSITRON NUCLIDE PROBE AND NUCLIDE MARKER, AND PREPARATION METHODS THEREFOR AND USES THEREOF 四川大学华西医院 2023-07-13 — — WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
US-20230144841-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2023-05-11 — — US disclosed
US-20230144841-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2023-05-11 — — US disclosed
EP-4161519-A1 PURINES AND METHODS OF THEIR USE Yumanity Therapeutics, Inc. (US) 2023-04-12 — — EP disclosed
US-9145366-B2 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides AKEBIA THERAPEUTICS, INC. (US) 2015-09-29 — — US disclosed
EP-2858990-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES AbbVie Inc. (US) 2015-04-15 — — EP disclosed
WO-2015017610-A1 SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2015-02-05 — — WO disclosed
WO-2013188381-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBVIE INC. (US) 2013-12-19 — — WO disclosed
US-20130018052-A1 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS SK CHEMICALS CO., LTD. (KR) 2013-01-17 — — US disclosed
US-20130018052-A1 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS SK CHEMICALS CO., LTD. (KR) 2013-01-17 — — US disclosed
US-20130018052-A1 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS SK CHEMICALS CO., LTD. (KR) 2013-01-17 — — US disclosed
WO-2012170377-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES AKEBIA THERAPEUTICS INC. (US) 2012-12-13 — — WO disclosed
US-20120309977-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES AKEBIA THERAPEUTICS INC. (US) 2012-12-06 — — US disclosed
US-20120309977-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES AKEBIA THERAPEUTICS INC. (US) 2012-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144841-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FAP, FIBP, FRS2 LPL 763/4885LIPG 1062/4885CA1 4653/4885
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 LPL 4578/4885LIPG 4457/4885CA1 4498/4885
US-20130018052-A1 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS ACVR1, ACVRL1, ALK LPL 2892/4885LIPG 2121/4885CA1 4184/4885
US-20230365529-A1 PARP7 INHIBITORS PARP1, PARP11, PARP2 LPL 4578/4885LIPG 4457/4885CA1 4498/4885
US-20120309977-A1 PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES HPD, APEH, ALDH7A1 LPL 1860/4885LIPG 2344/4885CA1 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.